Back to top

H.C. Wainwright Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Beam Therapeutics today and set a price target of $80.00. The company’s shares ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Beam Therapeutics Inc. (BEAM)